Pursuant to Regulation 29 of the Securities and Exchange Board of India (LODR) Regulations, 2015, MPS Pharmaa has informed that as per the requirements of Regulation 33 of the Securities and Exchange Board of India (LODR) Regulations, 2015, a meeting of the Board of Directors of the company is scheduled to be held on Thursday, 28th May, 2026 at 12:00 pm at the corporate office of the company at 703, Arunachal Building, 19, Barakhambha Road, Connaught Place, New Delhi-110001, to transact the following business: 1. To consider and approve the Audited Financial Results of the Company for the quarter and Financial Year ended 31st March, 2026. 2. To consider and approve the Auditors’ Report on the Audited Financial Results of the Company for the quarter and Financial Year ended 31st March, 2026. 3. To consider the appointment of Sanghi & Co., Chartered Accountants as the Internal Auditor of the Company for the F.Y. 2026-27. 4. To carry on any other business with the permission of the Board. Further, pursuant to BSE Circular no. LIST/COMP/01/2019-20 dated April 02, 2019 and in accordance with Code of Conduct for Prevention of Insider Trading framed by the Company pursuant to the SEBI (Prohibition of Insider Trading) Regulation, 2015, the trading window for dealing in the shares of the Company for all Directors/Officers/Designated Employees of the Company and their relatives, is already closed for the purpose of declaration of Audited Financial Results for the quarter and Financial Year ended 31st March, 2026. Accordingly, the trading window of the company shall remain closed till 30th May, 2026.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1807.25 |
| Dr. Reddys Lab | 1273.90 |
| Cipla | 1388.80 |
| Zydus Lifesciences | 1104.35 |
| Lupin | 2292.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: